All News
Patient Education handout on Raynaud’s Phenomenon https://t.co/cm77mmmPSi https://t.co/GimQXHBdpp
Dr. John Cush RheumNow ( View Tweet)
“Medicine is a science of uncertainty and an art of probability.” - Sir William Osler https://t.co/SQH3JZcDfv
Dr. John Cush RheumNow ( View Tweet)
Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Sponsored by Amgen
https://t.co/dGRgtfNtXu https://t.co/0G9o5ZPGUF
Dr. John Cush RheumNow ( View Tweet)
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Sponsored by Sanofi
https://t.co/1t5fsQKJOk https://t.co/B6Rjvebgs1
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
Sponsored by UCB
https://t.co/u615dX7DVu https://t.co/SAwoLJHJKt
Dr. John Cush RheumNow ( View Tweet)
Targeting Obesity in Rheumatic Disease Patients
Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese.
https://t.co/OYtsbfJQ2e https://t.co/xEZI3mkY0q
Dr. John Cush RheumNow ( View Tweet)
Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis
A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/MaWx6AZ0JF
Dr. John Cush RheumNow ( View Tweet)
Effectiveness of IL-6 Receptor Inhibitors versus Methotrexate or any Conventional Immunomodulators in Patients with Steroid Refractory Polymyalgia Rheumatica
Sponsored by Sanofi
https://t.co/K2IW3ECDTp https://t.co/wJFeHkKpGI
Dr. John Cush RheumNow ( View Tweet)
Increasing Prevalence of Osteoporosis
Research published in Osteoporosis International studied NHANES data showed increasing trends in osteoporosis in the United States of America.
https://t.co/KHWdMgjG0P https://t.co/lfXZA9F2JX
Dr. John Cush RheumNow ( View Tweet)
Autoimmune Disease Impact Report
Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: https://t.co/x3l9HIDul8
Dr. John Cush RheumNow ( View Tweet)
NP and PA Growth in the USA
Forbes has published a thoughtful perspective on the declining number of US physicians and the growth in the number of advanced practice providers or APPs in the US clinical workforce.
https://t.co/3Am8ZfEFo1 https://t.co/HeYfHc03Lu https://t.co/6H5wuf5RJ0
Dr. John Cush RheumNow ( View Tweet)
In 2021 the global rheumatoid arthritis market was valued at USD 22.77 billion and is expected to reach USD 33.30 billion by 2030. https://t.co/0vU6QP9JiG https://t.co/a8jXwk3KbK
Links:
Dr. John Cush RheumNow ( View Tweet)
Adrenal Dysfunction after Steroids in PMR and GCA Patients
JAMA has published a study of PMR and GCA patients who stopped glucocorticoid (GC) therapy and noted a low (1.2%) risk of GC-induced adrenal insufficiency after planned cessation.
https://t.co/zQSa8ex9na https://t.co/gkKxHFPuNe
Dr. John Cush RheumNow ( View Tweet)
Korea National Health Insurance Database review shows that risk of mortality in Behcets patients is 28% higher than gen. population; highest in 1st 12 mos (OR 2.66). Major causes were CA, CVD, GI (viscus rupture), respiratory, & infections. Higher in younger pts. https://t.co/vWJrUN9C0H
Dr. John Cush RheumNow ( View Tweet)
MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/8zJ0OBWjbm
Dr. John Cush RheumNow ( View Tweet)
If COVID was responsible for causing autoimmune Dz (AD), it is possible that Molecular mimicry was in play. Study shows 10nsequence homology between SARS-CoV-2 & AD epitopes; 2) similar MHC binding; 3) of high empirical immunogenicity. https://t.co/WO3gjxhVBw https://t.co/QdqtQMHcpL
Dr. John Cush RheumNow ( View Tweet)
Researchers have developed a machine learning model capable of predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis. In the KURAMA cohort of 210 SN patients, 57 (27%) progressed to RA. The FNN model excelled with an AUC of 0.924 and 81% https://t.co/b8G2AzMZ7m
Dr. John Cush RheumNow ( View Tweet)
Phase 3 RCT shows that SC Abatacept was not effective in treating Active Idiopathic Inflammatory Myopathy: 148 (double-blind) & 133 (OL) pts Rx for 24wks with similar improvement 56% ABA vs 42.5% PBO (P = 0.083); NS at 52 wks & w/ dermatomyositis. https://t.co/InlHJSmiKn https://t.co/mtFQWp3vlb
Dr. John Cush RheumNow ( View Tweet)
EUSTAR database study of 17,805 scleroderma (SSc) pts, 468 (2.6%) used HCQ with no effect on or improvement on HAQ-DI, or hand function scores when comparing HCQ users to non-HCQ users. https://t.co/Tu4tfG74pn https://t.co/Kckx3zTiJ4
Dr. John Cush RheumNow ( View Tweet)
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/0i5ZMJSxnp https://t.co/zeQ7QhmA0n
Dr. John Cush RheumNow ( View Tweet)